What is HC Wainwright’s Forecast for DNLI FY2027 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at HC Wainwright lifted their FY2027 EPS estimates for Denali Therapeutics in a report released on Thursday, March 26th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.41) per share for the year, up from their prior estimate of ($1.52). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2028 earnings at ($0.18) EPS, FY2029 earnings at $0.97 EPS and FY2030 earnings at $2.44 EPS.

Other analysts also recently issued research reports about the stock. Wedbush decreased their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. BTIG Research increased their price objective on Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group raised their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group began coverage on Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating for the company. Finally, Stifel Nicolaus upped their target price on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $18.16 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -6.11 and a beta of 1.02. The firm has a 50-day moving average of $20.43 and a two-hundred day moving average of $17.87. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter in the previous year, the company posted ($0.67) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DNLI. Headlands Technologies LLC bought a new position in shares of Denali Therapeutics in the 2nd quarter worth $26,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics during the third quarter valued at about $29,000. State of Wyoming bought a new stake in Denali Therapeutics during the second quarter valued at about $29,000. Aster Capital Management DIFC Ltd purchased a new position in Denali Therapeutics in the fourth quarter valued at about $57,000. Finally, Quarry LP purchased a new position in Denali Therapeutics in the third quarter valued at about $64,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.